TL;DR
This study identifies FARS2, a gene crucial for mitochondrial protein synthesis, as a novel cause of hypertrophic cardiomyopathy (HCM). By disrupting mitochondrial homeostasis and the quality control system, FARS2 deficiency leads to heart failure and premature death, suggesting new diagnostic and therapeutic avenues for this common heart disease.
What Problem Does This Paper Address?
Hypertrophic cardiomyopathy (HCM) is a prevalent genetic heart disease, yet a significant portion of affected individuals lack identifiable genetic causes. While many known HCM genes relate to sarcomeric proteins, the role of genes involved in mitochondrial function, particularly those essential for mitochondrial protein synthesis, has been less explored. This paper addresses this gap by investigating FARS2, a mitochondrial phenylalanyl-tRNA synthetase, as a potential novel pathogenic gene in HCM. The study aims to elucidate how FARS2 deficiency impacts heart function and to understand the underlying molecular mechanisms, specifically focusing on mitochondrial homeostasis and the mitochondrial quality control (MQC) system.
Methods
The researchers employed a multi-pronged approach:
- Human Genetic Studies: Whole-exome sequencing and Sanger sequencing were used to identify FARS2 variants in patients with HCM.
- In Vivo Models:
- Mice: A heart-specific inducible conditional knockout (icKO) mouse model was engineered to specifically delete Fars2 in cardiac tissue. A heterozygous Fars2 conditional mutant mouse model (cMut/-) was also created.
- Zebrafish: Fars2-knockdown zebrafish were generated to study the effects of Fars2 deficiency in a different vertebrate model.
- In Vitro Models: Fars2-knockdown neonatal rat ventricular myocytes (NRVMs) were used to investigate cellular mechanisms.
- Molecular and Cellular Analyses:
- RNA sequencing was performed to assess gene expression changes.
- Mitochondrial functional analyses included measuring oxygen consumption rate (OCR), mitochondrial membrane potential (ΔΨm), reactive oxygen species (ROS) production, ATP levels, and NAD+/NADH ratio.
- Transmission electron microscopy was used to examine mitochondrial ultrastructure.
- Immunofluorescence and Western blotting were employed to assess protein expression and localization, particularly for MQC components (e.g., LC3, p62, PINK1, Parkin, DRP1, MFN1/2, OPA1).
- Molecular docking was used to predict the impact of variants on enzyme activity.
- Therapeutic Interventions:
- Inhibitors of mitochondrial fission (Mdivi-1) and autophagy (3-methyladenine) were used in vitro.
- Adeno-associated virus 9 (AAV9)-mediated delivery of shRNA against Drp1 (to inhibit fission) and overexpression of Mfn1 (to promote fusion) were tested in vivo.
Datasets
Not explicitly detailed as separate datasets, but the study utilized:
- Patient Samples: Myocardial tissues from patients with HCM.
- Genetic Data: Whole-exome sequencing data from patients.
- Animal Models: Data generated from Fars2 icKO mice, heterozygous Fars2 mutant mice, and Fars2-knockdown zebrafish.
- Cellular Models: Data from Fars2-knockdown NRVMs and HeLa/A549 cell lines.
- RNA Sequencing Data: Transcriptomic data from mouse hearts.
Key Insights and Ideas
- FARS2 as a Novel HCM Gene: This study firmly establishes FARS2 as a previously unrecognized pathogenic gene in heritable cardiomyopathy, specifically HCM.
- Mitochondrial Quality Control is Central: The core mechanism identified is the disruption of the mitochondrial quality control (MQC) system. FARS2 deficiency doesn't just impair mitochondrial function; it throws the entire system of maintaining healthy mitochondria into disarray.
- Dynamic Imbalance: FARS2 deficiency leads to an imbalance in mitochondrial dynamics, characterized by increased fission and decreased fusion, resulting in fragmented mitochondria.
- Autophagy Dysregulation: The study reveals a complex interplay with autophagy. While autophagy is initially upregulated to clear damaged mitochondria, it becomes dysregulated and ultimately inhibited in later stages, contributing to the accumulation of dysfunctional organelles.
- Therapeutic Potential in MQC Modulation: Intervening in mitochondrial dynamics (fission/fusion) and autophagy pathways, even with small molecules or gene therapy vectors, can partially restore mitochondrial homeostasis and ameliorate cardiac dysfunction, offering promising therapeutic avenues.
Key Results
- Human Variants: Seven novel FARS2 variants were identified in HCM patients, all categorized as variants of uncertain significance but showing reduced expression, impaired localization, or decreased enzymatic activity in cellular models.
- Mouse Models: Heart-specific Fars2 knockout mice exhibited cardiac hypertrophy, left ventricular dilation, progressive heart failure, mitochondrial dysfunction, and significantly shortened lifespan, with sudden death occurring. Heterozygous mutant mice showed a tendency towards hypertrophy.
- Zebrafish Models: Fars2-knockdown zebrafish displayed pericardial edema and heart failure.
- Cellular Mechanisms: Fars2 deficiency in NRVMs led to decreased ATP production, impaired mitochondrial membrane potential, increased ROS, and altered NAD+/NADH ratio, indicating severe mitochondrial dysfunction.
- MQC Disruption: In icKO mice, the MQC system was significantly disrupted, with altered expression of key proteins involved in mitochondrial dynamics (DRP1, MFN1/2, OPA1) and autophagy (LC3, p62, PINK1, Parkin).
- Therapeutic Efficacy: Treatment with Mdivi-1 or 3-methyladenine in vitro, and AAV9-mediated Drp1 knockdown or Mfn1 overexpression in vivo, attenuated cardiac hypertrophy, improved cardiac function, and prolonged survival in Fars2-deficient models.
Limitations and Future Work
- Homozygosity Explanation: The exact reason for the homozygous FARS2R415L variant in one patient remains unclear due to the unavailability of parental samples, though potential explanations like complex structural variations are discussed.
- Variant Pathogenicity: While seven variants were identified, further studies are needed to definitively confirm the pathogenicity of all identified variants and their specific contribution to HCM phenotypes.
- Therapeutic Specificity: While MQC modulation showed promise, the authors suggest exploring upstream signals of the MQC system as alternative therapeutic targets.
- Broader Implications: Future research should aim to comprehensively validate the effectiveness of MQC system targeting for FARS2-associated cardiomyopathy and other mitochondrial translation deficiency-related HCMs.
- Sudden Death Mechanism: Further investigation is required to pinpoint the precise cause of sudden death observed in the Fars2-deficient models.
- Tissue-Specific Differences: The study notes that honeycomb cristae and increased mtDNA levels observed in late-stage icKO hearts might be tissue-specific features and warrants further investigation across different mtARS variants and tissues.
Summary updated